Literature DB >> 31314136

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.

Tareq A Juratli1,2,3, Pamela S Jones1, Nancy Wang2, Megha Subramanian2, Simon J B Aylwin4, Yazmin Odia5, Elham Rostami6,7, Olafur Gudjonsson6, Brian L Shaw2, Daniel P Cahill1, Evanthia Galanis8, Fred G Barker1, Sandro Santagata9, Priscilla K Brastianos2.   

Abstract

Entities:  

Year:  2019        PMID： 31314136      PMCID： PMC7032527          DOI： 10.1002/cncr.32197

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  19 in total

1.  BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.

Authors:  Ashley Roque; Yazmin Odia
Journal:  CNS Oncol       Date:  2017-04

Review 2.  Consequences of craniopharyngioma surgery in children.

Authors:  Hermann L Müller
Journal:  J Clin Endocrinol Metab       Date:  2011-04-20       Impact factor: 5.958

Review 3.  Craniopharyngiomas: an update.

Authors:  Bakhtiar Yamini; Malini Narayanan
Journal:  Expert Rev Anticancer Ther       Date:  2006-09       Impact factor: 4.512

4.  Modern radiotherapy approaches in the management of craniopharyngiomas.

Authors:  Robert I Smee; Janet R Williams; Bernard Kwok; Charlie Teo; Warwick Stening
Journal:  J Clin Neurosci       Date:  2011-05       Impact factor: 1.961

5.  Risk factors for the development of obesity in children surviving brain tumors.

Authors:  Robert H Lustig; Susan R Post; Kleebsabai Srivannaboon; Susan R Rose; Robert K Danish; George A Burghen; Xiaoping Xiong; Shengjie Wu; Thomas E Merchant
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

6.  Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Authors:  Marcia S Brose; Maria E Cabanillas; Ezra E W Cohen; Lori J Wirth; Todd Riehl; Huibin Yue; Steven I Sherman; Eric J Sherman
Journal:  Lancet Oncol       Date:  2016-07-23       Impact factor: 41.316

7.  The descriptive epidemiology of craniopharyngioma.

Authors:  G R Bunin; T S Surawicz; P A Witman; S Preston-Martin; F Davis; J M Bruner
Journal:  J Neurosurg       Date:  1998-10       Impact factor: 5.115

8.  Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.

Authors:  Sven-Martin Schlaffer; Michael Buchfelder; Robert Stoehr; Rolf Buslei; Annett Hölsken
Journal:  Front Genet       Date:  2018-02-22       Impact factor: 4.599

9.  Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.

Authors:  Elham Rostami; Petra Witt Nyström; Sylwia Libard; Johan Wikström; Olivera Casar-Borota; Olafur Gudjonsson
Journal:  Acta Neurochir (Wien)       Date:  2017-09-16       Impact factor: 2.216

10.  Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.

Authors:  Qi Yue; Yang Yu; Zhifeng Shi; Yongfei Wang; Wei Zhu; Zunguo Du; Zhenwei Yao; Liang Chen; Ying Mao
Journal:  J Neurosurg       Date:  2017-10-06       Impact factor: 5.115
View more
  17 in total

1.  BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.

Authors:  Sabeeh-Ur-Rehman Butt; Alberto Mejias; Cristina Morelli; Gonzalo Torga; Marlene Happe; Anna Patrikidou; Hendrik-Tobias Arkenau
Journal:  Cancer Chemother Pharmacol       Date:  2021-02-03       Impact factor: 3.333

Review 2.  Strictly third ventricle craniopharyngiomas: pathological verification, anatomo-clinical characterization and surgical results from a comprehensive overview of 245 cases.

Authors:  Ruth Prieto; Laura Barrios; José M Pascual
Journal:  Neurosurg Rev       Date:  2021-08-27       Impact factor: 3.042

3.  Duct-like diverticulum at the base of third ventricle tumors: a morphological signature diagnostic of papillary craniopharyngioma.

Authors:  José María Pascual; Ruth Prieto; Rodrigo Carrasco; Laura Barrios
Journal:  Neurosurg Rev       Date:  2022-08-19       Impact factor: 2.800

4.  Duct-like Recess in the Infundibular Portion of Third Ventricle Craniopharyngiomas: An MRI Sign Identifying the Papillary Type.

Authors:  J M Pascual; R Carrasco; L Barrios; R Prieto
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-11       Impact factor: 4.966

5.  90-Day Bundled Payment Simulation, Health Care Utilization, and Complications following Craniopharyngioma Resection in Adult Patients.

Authors:  Nicholas Dietz; Mayur Sharma; Kevin John; Dengzhi Wang; Beatrice Ugiliweneza; Sriprakash Mokshagundam; Martin F Bjurström; Maxwell Boakye; Brian J Williams; Norberto Andaluz
Journal:  J Neurol Surg B Skull Base       Date:  2021-12-16

6.  Genetic characterization of a case of sellar metastasis from bronchial carcinoid neuroendocrine tumor.

Authors:  Hong Christopher S; Adam J Kundishora; Aladine A Elsamadicy; Andrew B Koo; Jason M Beckta; Declan McGuone; E Zeynep Erson-Omay; Sacit Bulent Omay
Journal:  Surg Neurol Int       Date:  2020-09-25

Review 7.  Medical Therapy for Craniopharyngiomas.

Authors:  Krystallenia I Alexandraki; Paraskevi Xekouki
Journal:  touchREV Endocrinol       Date:  2021-11-08

8.  Integrative Analysis of Biomarkers and Mechanisms in Adamantinomatous Craniopharyngioma.

Authors:  Da Lin; Wenyue Zhao; Jun Yang; Hao Wang; Hongbing Zhang
Journal:  Front Genet       Date:  2022-03-30       Impact factor: 4.599

9.  In Reply: A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.

Authors:  Shingo Fujio; Tareq A Juratli; Daniel P Cahill; Fred G Barker; Priscilla K Brastianos
Journal:  Neurosurgery       Date:  2019-11-01       Impact factor: 4.654

Review 10.  Management of Craniopharyngiomas in the Era of Molecular Oncological Therapies: Not a Panacea.

Authors:  Hoong-Wei Gan
Journal:  J Endocr Soc       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.